Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

RxSight (RXST) Interest & Investment Income (2020 - 2026)

RxSight filings provide 6 years of Interest & Investment Income readings, the most recent being $2.2 million for Q4 2025.

  • On a quarterly basis, Interest & Investment Income fell 18.91% to $2.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $9.3 million, a 1.49% decrease, with the full-year FY2025 number at $9.3 million, down 1.5% from a year prior.
  • Interest & Investment Income hit $2.2 million in Q4 2025 for RxSight, down from $2.4 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $2.9 million in Q3 2024 to a low of $10000.0 in Q4 2021.
  • Median Interest & Investment Income over the past 5 years was $1.6 million (2023), compared with a mean of $1.3 million.
  • Biggest five-year swings in Interest & Investment Income: plummeted 89.8% in 2021 and later surged 8260.0% in 2022.
  • RxSight's Interest & Investment Income stood at $10000.0 in 2021, then surged by 8260.0% to $836000.0 in 2022, then skyrocketed by 98.68% to $1.7 million in 2023, then surged by 62.97% to $2.7 million in 2024, then decreased by 18.91% to $2.2 million in 2025.
  • The last three reported values for Interest & Investment Income were $2.2 million (Q4 2025), $2.4 million (Q3 2025), and $2.3 million (Q2 2025) per Business Quant data.